Relevant bibliographies by topics / Single-arm trial

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Single-arm trial'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Single-arm trial.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Single-arm trial"

1

Lasch, Florian, Kristina Weber, Mwe Mwe Chao, and Armin Koch. "A plea to provide best evidence in trials under sample-size restrictions: the example of pioglitazone to resolve leukoplakia and erythroplakia in Fanconi anemia patients." Orphanet Journal of Rare Diseases 12, no. 1 (2017): 102. https://doi.org/10.1186/s13023-017-0655-8.

Full text
Abstract:
In planning a clinical trial for demonstrating the efficacy of pioglitazone to resolve leukoplakia and erythroplakia in Fanconi anemia patients we had to discuss the need for a randomized controlled trial particularly under sample-size restrictions as very promising results were available from a single-arm clinical trial. Unfortunately, at a later stage, we had to suffer from the fact that single-arm clinical trials may sometimes mislead. When revisiting our planning at a later stage of a grant application, results of a randomized controlled trial had become available which were less impressiv
APA, Harvard, Vancouver, ISO, and other styles
2

Zou, Denise, Eileen Zhang, Sherry Wu, and Virgil Rose. "Use of Single-Arm Trials in FDA Approvals of Treatments in Relapsed or Refractory B-Cell Lymphoma." Blood 142, Supplement 1 (2023): 7250. http://dx.doi.org/10.1182/blood-2023-189855.

Full text
Abstract:
Background: Single-arm trials are commonly used to evaluate therapies targeting life-threatening or rare diseases (e.g., late-stage cancers that are relapsed or refractory to prior interventions). A number of oncology products supported by single-arm trials have been approved by the United States Food and Drug Administration (FDA). The draft guidance issued by the FDA on 24 March 2023 recommended key considerations for trial design and analysis when a single-arm trial is considered appropriate to support accelerated approval. The objective of this study was to assess how often anticancer drugs
APA, Harvard, Vancouver, ISO, and other styles
3

Estey, Elihu H., and Peter F. Thall. "New designs for phase 2 clinical trials." Blood 102, no. 2 (2003): 442–48. http://dx.doi.org/10.1182/blood-2002-09-2937.

Full text
Abstract:
AbstractConventional phase 2 clinical trials are typically single-arm experiments, with outcome characterized by one binary “response” variable. Clinical investigators are poorly served by such conventional methodology. We contend that phase 2 trials are inherently comparative, with the results of the comparison determining whether to conduct a subsequent phase 3 trial. When different treatments are studied in separate single-arm trials, actual differences between response rates associated with the treatments, “treatment effects,” are confounded with differences between the trials, “trial effe
APA, Harvard, Vancouver, ISO, and other styles
4

Grayling, Michael J., Munyaradzi Dimairo, Adrian P. Mander, and Thomas F. Jaki. "A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials." JNCI: Journal of the National Cancer Institute 111, no. 12 (2019): 1255–62. http://dx.doi.org/10.1093/jnci/djz126.

Full text
Abstract:
AbstractHistorically, phase II oncology trials assessed a treatment’s efficacy by examining its tumor response rate in a single-arm trial. Then, approximately 25 years ago, certain statistical and pharmacological considerations ignited a debate around whether randomized designs should be used instead. Here, based on an extensive literature review, we review the arguments on either side of this debate. In particular, we describe the numerous factors that relate to the reliance of single-arm trials on historical control data and detail the trial scenarios in which there was general agreement on
APA, Harvard, Vancouver, ISO, and other styles
5

Shi, Haolun, and Guosheng Yin. "Two-stage seamless transition design from open-label single-arm to randomized double-arm clinical trials." Statistical Methods in Medical Research 27, no. 1 (2016): 158–71. http://dx.doi.org/10.1177/0962280215625681.

Full text
Abstract:
Conventional phase II clinical trials use either a single- or multi-arm comparison scheme to examine the therapeutic effects of the experimental drug. Both single- and multi-arm evaluations have their own merits; for example, single-arm phase II trials are easy to conduct and often require a smaller sample size, while multiarm trials are randomized and typically lead to a more objective comparison. To bridge the single- and double-arm schemes in one trial, we propose a two-stage design, in which the first stage takes a single-arm comparison of the experimental drug with the standard response r
APA, Harvard, Vancouver, ISO, and other styles
6

Mossop, Helen, Michael J. Grayling, Ferdia A. Gallagher, Sarah J. Welsh, Grant D. Stewart, and James M. S. Wason. "Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials." British Journal of Cancer 126, no. 2 (2021): 204–10. http://dx.doi.org/10.1038/s41416-021-01613-5.

Full text
Abstract:
Abstract Background Efficient trial designs are required to prioritise promising drugs within Phase II trials. Adaptive designs are examples of such designs, but their efficiency is reduced if there is a delay in assessing patient responses to treatment. Methods Motivated by the WIRE trial in renal cell carcinoma (NCT03741426), we compare three trial approaches to testing multiple treatment arms: (1) single-arm trials in sequence with interim analyses; (2) a parallel multi-arm multi-stage trial and (3) the design used in WIRE, which we call the Multi-Arm Sequential Trial with Efficient Recruit
APA, Harvard, Vancouver, ISO, and other styles
7

Yin, Xiang, Ruthanna Davi, Elizabeth B. Lamont, et al. "Abstract 1025: Phase Ib trial single-arm efficacy estimates via comparison to a historical clinical trial synthetic control arm." Cancer Research 82, no. 12_Supplement (2022): 1025. http://dx.doi.org/10.1158/1538-7445.am2022-1025.

Full text
Abstract:
Abstract Background: Innovations in data science and trial design have catalyzed novel clinical research methods which may inform the future success of new experimental therapies more efficiently than previously believed. To guide development of the novel immune agent GEN-1, we compared endpoints experienced by patients from a recent neoadjuvant single-arm phase Ib study of GEN-1 plus standard chemotherapy to those of similar historical clinical trial patients in receipt of standard chemotherapy alone. Methods: To compare safety and efficacy endpoints following first-line neoadjuvant weekly GE
APA, Harvard, Vancouver, ISO, and other styles
8

Hahn, Andreas, Ulrike Loderstädt, Hagen Frickmann, and Norbert G. Schwarz. "Sparing the control arm using well-characterized diagnostic approaches – the Gart and Buck prevalence estimator for efficacy estimation in single-arm trials." Journal of Laboratory Medicine 43, no. 5 (2019): 279–81. http://dx.doi.org/10.1515/labmed-2019-0091.

Full text
Abstract:
Abstract Efficacy estimation of medical interventions in clinical trials requires diagnostics to assess the study endpoint. The imperfect nature of diagnostics often leads to biased efficacy estimations, usually underestimation, that could result in failure of clinical trials. Adjustment methods can be used if sensitivity and specificity are known, but they are not regularly applied. Double-arm clinical trials are the standard for demonstrating the superiority of a medical intervention. However, sometimes single-arm trials are the only option: for example, if a parallel group trial design with
APA, Harvard, Vancouver, ISO, and other styles
9

Alexander, Brian Michael, Patrick Y. Wen, Eudocia Quant Lee, et al. "Bayesian adaptive randomized trial design for patients with recurrent glioblastoma." Journal of Clinical Oncology 30, no. 15_suppl (2012): 2005. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2005.

Full text
Abstract:
2005 Background: Bayesian-based trial design has the ability to utilize accumulating data in real time to alter the course of the trial, thereby enabling dynamic allocation to experimental arms and earlier dropping of ineffective arms. This flexibility results in a potentially more efficient trial framework by increasing the probability of enrollment to arms that show evidence of efficacy. In this study we considered a hypothetical scenario in which patients who have been previously treated on several separate experimental protocols at the Dana-Farber/Harvard Cancer Center and the University o
APA, Harvard, Vancouver, ISO, and other styles
10

Wu, Jianrong. "Single-arm Phase II cancer survival trial designs." Journal of Biopharmaceutical Statistics 26, no. 4 (2016): 644–56. http://dx.doi.org/10.1080/10543406.2015.1052494.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Single-arm trial"

1

Liu, Meng. "A PREDICTIVE PROBABILITY INTERIM DESIGN FOR PHASE II CLINICAL TRIALS WITH CONTINUOUS ENDPOINTS." UKnowledge, 2017. http://uknowledge.uky.edu/epb_etds/15.

Full text
Abstract:
Phase II clinical trials aim to potentially screen out ineffective and identify effective therapies to move forward to randomized phase III trials. Single-arm studies remain the most utilized design in phase II oncology trials, especially in scenarios where a randomized design is simply not practical. Due to concerns regarding excessive toxicity or ineffective new treatment strategies, interim analyses are typically incorporated in the trial, and the choice of statistical methods mainly depends on the type of primary endpoints. For oncology trials, the most common primary objectives in phase I
APA, Harvard, Vancouver, ISO, and other styles
2

MOLICA, MATTEO. "Title: Cladribine, idarubicin and cytarabine (CLIA1) in patients with acute myeloid leukemia (AML): a phase 2 single-arm trial." Doctoral thesis, 2020. http://hdl.handle.net/11573/1350197.

Full text
Abstract:
Introduction: Several studies have demonstrated that the addition of cladribine (CdA) to standard cytarabine containing induction regimens improve outcomes for patients with newly diagnosed and relapsed/refractory (RR) acute myeloid leukemia (AML) patients. Based on this experience, we conducted a phase-2 clinical trial to study the efficacy of CdA combined with a higher dose of cytarabine (ARA-C) and idarubicin (IDA) as induction and consolidation treatment in younger patients with AML. Aim and Methods: In this single-arm, open-label, single-centre phase 2 study, we enrolled 153 patients aged
APA, Harvard, Vancouver, ISO, and other styles
3

"Male circumcision as a bio-medical HIV intervention targeting male heterosexual sexually transmitted disease (STD) patients in China: an acceptability study and a single-arm test-of-concept trial." 2013. http://library.cuhk.edu.hk/record=b5884445.

Full text
Abstract:
Wang, Zixin.<br>Thesis (Ph.D.)--Chinese University of Hong Kong, 2013.<br>Includes bibliographical references (leaves 215-223).<br>Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web.<br>Abstract and appendixes also in Chinese.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Single-arm trial"

1

Feldman, Brian Michael. Evaluation of a new single-arm radomized placebo phase design clinical trial using Monte Carlo computer simulation. National Library of Canada, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wu, Jianrong. Single-Arm Phase II Survival Trial Design. Taylor & Francis Group, 2021.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wu, Jianrong. Single-Arm Phase II Survival Trial Design. Taylor & Francis Group, 2021.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wu, Jianrong. Single-Arm Phase II Survival Trial Design. Taylor & Francis Group, 2021.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wu, Jianrong. Single-Arm Phase II Survival Trial Design. Taylor & Francis Group, 2021.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Single-Arm Phase II Survival Trial Design. CRC Press LLC, 2023.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Single-arm trial"

1

Pan, Haitao, and Ying Yuan. "Single Arm Phase II Clinical Trial." In Bayesian Adaptive Design for Immunotherapy and Targeted Therapy. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-8176-0_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wu, Jianrong. "Phase II Immunotherapy Trial Design." In Single-Arm Phase II Survival Trial Design. Chapman and Hall/CRC, 2021. http://dx.doi.org/10.1201/9781003129059-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wu, Jianrong. "Bayesian Single-Arm Phase II Trial Design." In Single-Arm Phase II Survival Trial Design. Chapman and Hall/CRC, 2021. http://dx.doi.org/10.1201/9781003129059-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wu, Jianrong. "Phase II Trial Design under Parametric Model." In Single-Arm Phase II Survival Trial Design. Chapman and Hall/CRC, 2021. http://dx.doi.org/10.1201/9781003129059-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wu, Jianrong. "Phase II Trial Design with GMI Endpoint." In Single-Arm Phase II Survival Trial Design. Chapman and Hall/CRC, 2021. http://dx.doi.org/10.1201/9781003129059-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wu, Jianrong. "Introduction of Single-Arm Phase II Trial Design." In Single-Arm Phase II Survival Trial Design. Chapman and Hall/CRC, 2021. http://dx.doi.org/10.1201/9781003129059-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wu, Jianrong. "Two-Stage Design Evaluating Survival Distributions." In Single-Arm Phase II Survival Trial Design. Chapman and Hall/CRC, 2021. http://dx.doi.org/10.1201/9781003129059-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wu, Jianrong. "Two-Stage Design Evaluating Survival Probabilities." In Single-Arm Phase II Survival Trial Design. Chapman and Hall/CRC, 2021. http://dx.doi.org/10.1201/9781003129059-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wu, Jianrong. "One-Stage Design Evaluating Survival Distributions." In Single-Arm Phase II Survival Trial Design. Chapman and Hall/CRC, 2021. http://dx.doi.org/10.1201/9781003129059-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wu, Jianrong. "One-Stage Design Evaluating Survival Probabilities." In Single-Arm Phase II Survival Trial Design. Chapman and Hall/CRC, 2021. http://dx.doi.org/10.1201/9781003129059-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Single-arm trial"

1

Hojjati, Amir, Seyed Ali Hoseini, Hossein Negahban, Ali Moradi, Ebrahim Ghayem Hassankhani, and Alireza Akbarzadeh. "Investigating the Effectiveness of Using the Hip Exoskeleton Assistive Robot (FUM-HEXA) on Endurance, Gait Symmetry, Stride Time and Cadence in Hemiplegic Stroke Patients: A Single-Arm Clinical Trial." In 2024 31st National and 9th International Iranian Conference on Biomedical Engineering (ICBME). IEEE, 2024. https://doi.org/10.1109/icbme64381.2024.10895861.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

M. Freitas, A., R. L. Thomaz, F. M. Lopes, and A. B. Soares. "SINGLE TRIAL EEG DECODING OF ARM EXTENSION AND FLEXION: A CASE STUDY." In Congresso Brasileiro de Eletromiografia e Cinesiologia (COBEC) e o Simpósio de Engenharia Biomédica (SEB) - COBECSEB. Even3, 2018. http://dx.doi.org/10.29327/cobecseb.78842.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Barbee, Lindley, Olusegun Soge, Jennifer Morgan, et al. "O06.1 Gentamicin for pharyngeal gonorrhea: a single-arm, non-blinded clinical trial." In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.134.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ramanan, Athimalaipet, Andrew DickDick, Ashley JonesJones, et al. "LB0011 A PHASE II SINGLE ARM (ADAPTIVE DESIGN) TRIAL OF TOCILIZUMAB IN ANTI-TNF REFRACTORY PATIENTS WITH JIA-ASSOCIATED UVEITIS (APTITUDE TRIAL)." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.8744.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Amano, K., K. Chino, Y. Okada, et al. "AB0984 Tocilizumab monotherapy for polymyalgia rheumatica ∼ results of 52-week treatment of a prospective, single-center, open, single-arm trial." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.4525.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Matulonis, Ursula A., Alexi Wright, Susana Campos, et al. "Abstract CT142: A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-ct142.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kondo, T., Y. Okada, A. Shibata, et al. "THU0577 Tocilizumab monotherapy for adult onset still's disease – results of 52-week treatment of a prospective, single-center, single-arm, open trial." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.4922.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wu, Chanyuan, Qian Wang, LI Mengtao, and Xiaofeng Zeng. "FRI0215 SIROLIMUS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS RELATED THROMBOCYTOPENIA (SLE-TP): A SINGLE-ARM, OPEN-LABEL CLINICAL TRIAL." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7068.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fendler, W. P., T. Bartel, K. Pabst, et al. "68Ga-FAPI-46 PET for imaging of FAP expressing cancer – a single-center prospective interventional single-arm clinical trial: study protocol and initial results." In 61. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin. Georg Thieme Verlag, 2023. http://dx.doi.org/10.1055/s-0043-1766250.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Coffman, Kelley, Yuta Myojin, Cecilia Monge, et al. "585 Ofranergene obadenovec (VB-111) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single-center, single-arm phase II trial." In SITC 38th Annual Meeting (SITC 2023) Abstracts. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/jitc-2023-sitc2023.0585.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Single-arm trial"

1

Gates, Allison, Michelle Gates, Shannon Sim, Sarah A. Elliott, Jennifer Pillay, and Lisa Hartling. Creating Efficiencies in the Extraction of Data From Randomized Trials: A Prospective Evaluation of a Machine Learning and Text Mining Tool. Agency for Healthcare Research and Quality (AHRQ), 2021. http://dx.doi.org/10.23970/ahrqepcmethodscreatingefficiencies.

Full text
Abstract:
Background. Machine learning tools that semi-automate data extraction may create efficiencies in systematic review production. We prospectively evaluated an online machine learning and text mining tool’s ability to (a) automatically extract data elements from randomized trials, and (b) save time compared with manual extraction and verification. Methods. For 75 randomized trials published in 2017, we manually extracted and verified data for 21 unique data elements. We uploaded the randomized trials to ExaCT, an online machine learning and text mining tool, and quantified performance by evaluati
APA, Harvard, Vancouver, ISO, and other styles
2

Li, Haitao, Gongwei Long, and Jun Tian. Efficacy and Safety of Photodynamic Therapy for Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.11.0043.

Full text
Abstract:
Review question / Objective: To comprehensively summarize the relevant clinical studies, and assess the efficacy and safety of PDT in the treatment of NMIBC. Eligibility criteria: (1) pathologically confirmed NMIBC; (2) included &gt; 5 patients who received PDT; (3) clinical studies including randomized-controlled trials, case-control studies, and single-arm reports; (4) included efficacy and/or safety results；(5) follow-up duration &gt; 6 months; (6) report was written in English or has a English abstract.
APA, Harvard, Vancouver, ISO, and other styles
3

Zheng, Jiaxi, and Haihua Yang. Clinical Benefits of Immune Checkpoint Inhibitors and Predictive Value of Tumor Mutation Burden in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.1.0008.

Full text
Abstract:
Review question / Objective: Is immunotherapy associated with beneficial clinical outcomes for hepatocellular carcinoma (HCC) and how can combination immunotherapy be deployed to produce the best benefit? Is tumor mutation burden (TMB) a predictive biomarker for immune‐checkpoint inhibitors? Condition being studied: To this date, about 50 single-arm clinical trials and several randomized control trials (RCTs) presented final or interim results of investigations on the efficacy of PD-1/PD-L1 inhibitors for advanced HCC. In the CheckMate 459, IMbrave 050, and ORIENT-32, immunotherapies were foun
APA, Harvard, Vancouver, ISO, and other styles
4

Selph, Shelley S., Andrea C. Skelly, Rebecca M. Jungbauer, et al. Cervical Degenerative Disease Treatment: A Systematic Review. Agency for Healthcare Research and Quality (AHRQ), 2023. http://dx.doi.org/10.23970/ahrqepccer266.

Full text
Abstract:
Objectives. Cervical degenerative disease (CDD) is common, becomes more prevalent with age, and is managed with surgical and nonoperative treatments to alleviate pain, improve function, and prevent progression or recurrence. This systematic review summarizes the evidence on treatments for CDD. Data sources. We searched Ovid MEDLINE®, Embase®, and Cochrane CENTRAL from 1980 to February 15, 2023; reference lists; and clinical trial registries. Review methods. Predefined criteria were used to identify studies; prespecified methods were used to assess study quality and strength of evidence for key
APA, Harvard, Vancouver, ISO, and other styles
5

Chen, Po-Wei, Hsiao-Yuan Su, Chih-Hsing Wu, et al. Association of Bisphosphonates with Risk of Incident Diabetes and Glycemic Control: A Protocol of Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.4.0125.

Full text
Abstract:
Review question / Objective: To determine the association between bisphosphonate use and the risk of incident diabetes and glycemic control in adults with updated evidence from clinical trials and observational studies. Eligibility criteria: The inclusion criteria for studies assessing risk of incident diabetes are as follows: (1) availability of data on bisphosphonate use in individuals without diabetes; (2) evaluation of the risk of diabetes for bisphosphonate users compared with controls; and (3) either clinical trials or observational studies. To assess effects of bisphosphonates on glycem
APA, Harvard, Vancouver, ISO, and other styles
6

Zhang, Hengdi, Yunming Li, Guangyu Chen, Fei Han, and Wei Jiang. Human amniotic membrane graft for refractory macular hole: a single-arm meta analysis and systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.2.0098.

Full text
Abstract:
Review question / Objective: Currently, pars plana vitrectomy (PPV) with ILM peeling is the gold standard treatment for full thickness macular hole (FTMH). Despite of the high macular hole closure rate, a refractory FTMH may occur. The next step for a recurrent or persistent MH is usually repeat PPV with extended ILM peeling. This is not always an option especially with high myopia patients or those who had already undergone an aggressive ILM peeling at initial surgery. A variety of novel techniques have been developed to address this issue, among which human amniotic membrane seems to be a pr
APA, Harvard, Vancouver, ISO, and other styles
7

Rankin, Nicole, Deborah McGregor, Candice Donnelly, et al. Lung cancer screening using low-dose computed tomography for high risk populations: Investigating effectiveness and screening program implementation considerations: An Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for the Cancer Institute NSW. The Sax Institute, 2019. http://dx.doi.org/10.57022/clzt5093.

Full text
Abstract:
Background Lung cancer is the number one cause of cancer death worldwide.(1) It is the fifth most commonly diagnosed cancer in Australia (12,741 cases diagnosed in 2018) and the leading cause of cancer death.(2) The number of years of potential life lost to lung cancer in Australia is estimated to be 58,450, similar to that of colorectal and breast cancer combined.(3) While tobacco control strategies are most effective for disease prevention in the general population, early detection via low dose computed tomography (LDCT) screening in high-risk populations is a viable option for detecting asy
APA, Harvard, Vancouver, ISO, and other styles
8

Xin, Yong, Youqi Zhu, Junjie Cui, Jiuzhou Chen, and Yufei Lou. Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemoradiotherapy for patients with locally advanced rectal cancer：A meta-analysis of single-arm trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.4.0094.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Shumway, Dean A., Kimberly S. Corbin, Magdoleen H. Farah, et al. Partial Breast Irradiation for Breast Cancer. Agency for Healthcare Research and Quality (AHRQ), 2023. http://dx.doi.org/10.23970/ahrqepccer259.

Full text
Abstract:
Objectives. To evaluate the comparative effectiveness and harms of partial breast irradiation (PBI) compared with whole breast irradiation (WBI) for early-stage breast cancer, and how differences in effectiveness and harms may be influenced by patient, tumor, and treatment factors, including treatment modality, target volume, dose, and fractionation. We also evaluated the relative financial toxicity of PBI versus WBI. Data sources. MEDLINE®, Embase®, Cochrane Central Registrar of Controlled Trials, Cochrane Database of Systematic Reviews, Scopus, and various grey literature sources from databa
APA, Harvard, Vancouver, ISO, and other styles
10

Wagner, Jesse, Hanan Aboumatar, and Jonathan R. Treadwell. Engaging Family Caregivers with Structured Communication for Safe Care Transitions. Agency for Healthcare Research and Quality (AHRQ), 2024. http://dx.doi.org/10.23970/ahrqepc_mhs4engaging.

Full text
Abstract:
Objectives. To summarize recent relevant literature on patient safety practices (PSPs) focused on engaging family caregivers with structured communication during care transitions and assess the effectiveness of these PSPs to improve safety during care transitions. This review provides information for clinicians, health system leaders, and policymakers to better inform approaches to engaging family caregivers with structured communication to improve safety during care transitions. Methods. We followed rapid review processes provided by the Agency for Healthcare Research and Quality Evidence-bas
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Single-arm trial' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography